Moderna trial had higher Serious Adverse Events than Pfizer due to Endotoxin ?

Moderna was patenting mRNA jabs using E. coli variety DH5α for cDNA assembly before the Covid19 pandemic and used Endotoxin contaminated jabs in their trial

Moderna¹ reported more Serious Adverse Events than Pfizer/BioNTech² during their respective large scale clinical trials.

Did the original Moderna dose-finding trial³ of only 660 people use mRNA from RT-PCR or E. coli?

Endotoxin contamination will be present from Moderna use of NEB DH5α (5H-alpha) Competent E. coli cells in making their jabs on a large scale, if they followed the method described in their patents.⁴

Pfizer and BioNTech used RT-PCR magnetic bead purified mRNA for their Pfizer Process 1 trial which yielded a virtually Endotoxin free product.⁵

Fraiman et al study sees renewed interest

A recent inerview of Dr Joseph Fraiman by Dr John Campbell discussed the fact that there were more Serious Adverse Events in the Moderna trial than in Pfizer, as Fraiman’s team reported.⁶

The Moderna trial exhibited 136 Serious Adverse Events per 10,000 jabbees compared to Pfizer/BioNTech 67.5 per 10,000.

US and UK worked together on Gain of Function

In 2015, researchers in US and UK reported their Gain of Function work⁷ using the DH5α strain of Escherichia coli to make recombinant DNA plasmids.

DH5α strain looks⁸ like this:

Each cell can shed over 1,000,000 supertoxin Lipid A fragments.⁹

Questions arising

Why did the Moderna trials also report a higher number of Serious Adverse Events in those who received Placebo?

Will add more later.

1. Moderna. A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19. https://classic.clinicaltrials.gov/ct2/show/NCT04470427

2. Pfizer and BioNTech. https://classic.clinicaltrials.gov/ct2/show/NCT04368728

3. Moderna. Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older. https://classic.clinicaltrials.gov/ct2/show/NCT04405076

4. Moderna Patent USUS20160032273A1. Shahrokh Z, Rohl I, Spivak BV, Chakraborty T, Aunins JG. 2014. Characterization of mrna molecules. https://patents.google.com/patent/US20160032273A1/en

5.

6. Fraiman J, Erviti J, Jones M, Greenland S, Whelan P, Kaplan RM and Doshi P. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. https://www.sciencedirect.com/science/article/pii/S0264410X22010283

7. Kostylev M, Otwell AE, Richardson RE and Suzuki Y. 2015. Cloning Should Be Simple: Escherichia coli DH5α-Mediated Assembly of Multiple DNA Fragments with Short End Homologies. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562628/

8. Wang Y, et al. 2020. Effects of Sr^2 + on the preparation of Escherchia coli DH5α competent cells and plasmid transformation. https://peerj.com/articles/9480/#

9.